Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction

Brief Summary

Serotonin and oxytocin play a role in fear conditioning and fear extinction learning, psychological processes that are critically involved in psychiatric disorders such as posttraumatic stress disorder (PTSD). Specifically, administration of oxytocin has been shown to facilitate fear extinction in humans. Similarly, substances that release serotonin and oxytocin such as MDMA have been shown to enhance the extinction of fear memory in animals. However, there are no data on the effects of MDMA on fear extinction in humans. Therefore, the primary aim of this study is to investigate the role of acute serotonin release in the effects of fear extinction. MDMA will be used as pharmacological tool to induce serotonin release in this study.

Intervention / Treatment

  • Drug: MDMA
  • Drug: Placebo

Condition or Disease

  • Healthy


Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 18 Years to 50 Years   (Adult)
Enrollment: 30 ()
Funded by: Other


Clinical Trial Dates

Start date: Oct 18, 2019
Primary Completion: Dec 10, 2020
Completion Date: Dec 24, 2020
Study First Posted: May 17, 2018
Results First Posted: Aug 30, 2020
Last Updated: Jan 19, 2022

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: Male
Minimum Age: 18
Maximum Age: 50

More Details

NCT Number: NCT03527316
Acronym: MFE
Other IDs: BASEC 2017-01947
Study URL: https://ClinicalTrials.gov/show/NCT03527316
Last updated: Jun 16, 2022